AKE

Arkema S.A. is a company caught between two identities. Born in 2006 as a spinoff of TotalEnergies' chemicals division, it has spent nearly two decades attempting to shed its commodity heritage and recast itself as a specialty materials champion. The strategy, driven with unusual consistency by CEO Thierry Le Henaff since inception, has been to acquire, build, and invest its way into high-value advanced materials while methodically divesting the more cyclical, lower-margin commodity businesses. By the mid-2020s, that transformation was supposed to be substantially complete. The market is now asking whether the result was worth the effort.

At a share price of approximately EUR 60.85, Arkema's market capitalization stands at roughly EUR 4.6 billion. This is a company with EUR 9.1 billion in revenue trading at 0.5 times sales and 5.7 times EBITDA. For a self-described specialty materials company, those are commodity-grade multiples. The central analytical question is not whether Arkema has improved its portfolio. It clearly has. The question is whether Arkema's specialty materials are actually specialty enough to command structural pricing power, or whether the company has simply migrated from one form of cyclicality to another, dressed in more sophisticated language.

The financial evidence from 2025 is sobering. Net income plunged 82% year over year, from EUR 354 million to EUR 63 million. Diluted EPS collapsed from EUR 4.49 to EUR 0.83. EBIT fell from EUR 537 million to EUR 420 million. The company missed analyst EPS estimates in every reported quarter, often by dramatic margins. In Q3 2025, Arkema delivered EPS of EUR 0.619 against a consensus estimate of EUR 1.53, a miss of nearly 60%. This is not ordinary cyclical softness. This is a company whose earnings trajectory has broken below what even cautious analysts anticipated, raising structural questions about the durability of its competitive position during demand downturns.

Arkema's story illuminates a broader truth about the European specialty chemicals sector: the label "specialty" does not automatically confer pricing power. The moat must be proven in the downturn, not during the boom. And in this downturn, Arkema's margins have compressed with a ferocity that undermines the specialty narrative.